Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The merger will facilitate the advancement of our broad pipeline of targeted oncology programs, including TPST-1495 and TPST-1120, which are both progressing in the clinic with encouraging early signs of clinical benefit.
Lead Product(s): TPST-1495
Therapeutic Area: Oncology Product Name: TPST-1495
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tempest Therapeutics
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Merger March 29, 2021
Details:
While MLE-301 was generally well-tolerated, the data do not support moving forward with its development in the target population of peri- and post-menopausal women, especially with the evolving dynamics of a highly competitive NK3R antagonist market.
Lead Product(s): MLE-301
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: MLE-301
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
The single ascending dose portion of the study will be conducted in healthy male volunteers, to determine the pharmacokinetics of MLE-301 and its pharmacodynamic profile as measured by reductions of biomarkers (luteinizing hormone, testosterone).
Lead Product(s): MLE-301
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: MLE-301
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
Livoletide did not achieve statistically significant improvement in primary endpoint of change in hyperphagia and food-related behaviors relative to placebo.
Lead Product(s): Livoletide
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020